- Home
- CPF vs URGN Comparison
CPF vs URGN Comparison
Compare CPF & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPF
- URGN
- Stock Information
- Founded
- CPF 1954
- URGN 2004
- Country
- CPF United States
- URGN United States
- Employees
- CPF N/A
- URGN N/A
- Industry
- CPF Major Banks
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- CPF Finance
- URGN Health Care
- Exchange
- CPF Nasdaq
- URGN Nasdaq
- Market Cap
- CPF 849.9M
- URGN 904.0M
- IPO Year
- CPF N/A
- URGN 2017
- Fundamental
- Price
- CPF $30.45
- URGN $18.10
- Analyst Decision
- CPF Buy
- URGN Strong Buy
- Analyst Count
- CPF 1
- URGN 8
- Target Price
- CPF $35.00
- URGN $28.50
- AVG Volume (30 Days)
- CPF 152.6K
- URGN 1.2M
- Earning Date
- CPF 10-29-2025
- URGN 11-05-2025
- Dividend Yield
- CPF 3.60%
- URGN N/A
- EPS Growth
- CPF 6.71
- URGN N/A
- EPS
- CPF 2.24
- URGN N/A
- Revenue
- CPF $253,738,000.00
- URGN $94,238,000.00
- Revenue This Year
- CPF $1.89
- URGN $39.63
- Revenue Next Year
- CPF $6.03
- URGN $111.49
- P/E Ratio
- CPF $13.39
- URGN N/A
- Revenue Growth
- CPF 6.60
- URGN 10.85
- 52 Week Low
- CPF $23.16
- URGN $3.42
- 52 Week High
- CPF $33.25
- URGN $21.71
- Technical
- Relative Strength Index (RSI)
- CPF 54.78
- URGN 44.77
- Support Level
- CPF $29.75
- URGN $17.89
- Resistance Level
- CPF $30.90
- URGN $21.71
- Average True Range (ATR)
- CPF 0.59
- URGN 1.17
- MACD
- CPF -0.20
- URGN -0.30
- Stochastic Oscillator
- CPF 32.41
- URGN 5.50
About CPF Central Pacific Financial Corp New
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.